• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium

Yazar
Marra, Giancarlo
Salonia, Andrea
Mir, Maria Carmen
Larcher, Alessandro
Montorsi, Francesco
Klatte, Tobias
Capitanio, Umberto
Rosiello, Giuseppe
Erdem, Selcuk
Rowe, Isaline
KARA, ÖNDER
Roussel, Eduard
Campi, Riccardo
Kriegmair, Maximilian C.
Sibona, Mattia
Bertolo, Riccardo
Ouzaid, Idir
Üst veri
Tüm öğe kaydını göster
Özet
Purpose To investigate the natural history and follow-up after kidney tumor treatment of Von Hippel-Lindau (VHL) patients. Materials and methods A multi-institutional European consortium of patients with VHL syndrome included 96 non-metastatic patients treated at 9 urological departments (1987-2018). Descriptive and survival analyses were performed. Results and limitations Median age at VHL diagnosis was 34 years (IQR 25-43). Two patients (2.1%) showed only renal manifestations at VHL diagnosis. Concomitant involvement of Central Nervous System (CNS) vs. pancreas vs. eyes vs. adrenal gland vs. others were present in 60.4 vs. 68.7 vs. 30.2 vs. 15.6 vs. 15.6% of patients, respectively. 45% of patients had both CNS and pancreatic diseases alongside kidney. The median interval between VHL diagnosis and renal cancer treatment resulted 79 months (IQR 0-132), and median index tumor size leading to treatment was 35.5 mm (IQR 28-60). Of resected malignant tumours, 73% were low grade. Of high-grade tumors, 61.1% were large > 4 cm. With a median follow-up of 8 years, clinical renal progression rate was 11.7% and 29.3% at 5 and 10 years, respectively. Overall mortality was 4% and 7.5% at 5 and 10 years, respectively. During the follow-up, 50% of patients did not receive a second active renal treatment. Finally, 25.3% of patients had CKD at last follow-up. Conclusions Mean period between VHL diagnosis and renal cancer detection is roughly three years, with significant variability. Although, most renal tumors are small low-grade, clinical progression and mortality are not negligible. Moreover, kidney function represents a key issue in VHL patients.
Bağlantı
http://hdl.handle.net/20.500.12627/1789
https://doi.org/10.1007/s00345-020-03574-5
Koleksiyonlar
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere Göre

Hesabım

GirişKayıt

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV